Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.24 USD
Change Today -0.02 / -1.59%
Volume 265.3K
DSCO On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

discovery laboratories inc (DSCO) Snapshot

Open
$1.26
Previous Close
$1.26
Day High
$1.27
Day Low
$1.24
52 Week High
07/7/14 - $2.03
52 Week Low
12/9/14 - $0.99
Market Cap
106.1M
Average Volume 10 Days
639.3K
EPS TTM
$-0.51
Shares Outstanding
85.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DISCOVERY LABORATORIES INC (DSCO)

Related News

No related news articles were found.

discovery laboratories inc (DSCO) Related Businessweek News

No Related Businessweek News Found

discovery laboratories inc (DSCO) Details

Discovery Laboratories, Inc., a specialty biotechnology company, focuses on developing products for critical-care patients with respiratory disease and improving care in pulmonary medicine. Its proprietary drug technology produces a synthetic peptide-containing surfactant (KL4 surfactant in liquid, lyophilized, and aerosolized dosage forms), as well as develops drug delivery technologies to enable efficient delivery of its aerosolized KL4 surfactant. The company offers SURFAXIN Intratracheal suspension for the prevention of respiratory distress syndrome (RDS) in premature infants; AFECTAIR device, a disposable aerosol-conducting airway connector for infants; and WARMING CRADLE, a dry-block heating device that is designed to warm drug vials at the same temperature that is designated in the SURFAXIN prescribing information. It is also developing AEROSURF, a drug/device combination product that delivers KL4 surfactant in aerosolized form using the lyophilized KL4 surfactant is in Phase II clinical trials for the treatment of RDS in premature infants. In addition, the company is developing a lyophilized (freeze-dried) dosage form of its KL4 surfactant. The company has a collaboration agreement with Battelle Memorial Institute for the development and commercialization of AEROSURF; and a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of KL4 surfactant products in Andorra, Greece, Italy, Portugal, and Spain. Discovery Laboratories, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.

110 Employees
Last Reported Date: 03/16/15
Founded in 1992

discovery laboratories inc (DSCO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $493.3K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $303.5K
Compensation as of Fiscal Year 2013.

discovery laboratories inc (DSCO) Key Developments

Discovery Laboratories, Inc. Completes Enrollment of AEROSURF Phase 2a Clinical Trial and Restructures

Discovery Laboratories Inc. announced that it has completed enrollment in its AEROSURF phase 2a clinical trial assessing the administration of a single dose of AEROSURF in premature infants 29-34 week gestational age (GA) with respiratory distress syndrome (RDS). The company also is implementing a restructuring plan to voluntarily cease the commercialization of SURFAXIN (lucinactant) Intratracheal Suspension and focus its resources on the development of its aerosolized KL4 surfactant for respiratory diseases, beginning with AEROSURF. AEROSURF: The AEROSURF phase 2a trial is a multi-center, open-label trial to evaluate safety and tolerability of a single dose of aerosolized KL4 surfactant in premature infants (n = 48) 29 to 34 weeks GA who are receiving nasal continuous positive airway pressure (nCPAP) for RDS, compared to infants receiving nCPAP alone. The study evaluated three escalating doses of AEROSURF. In addition to evaluating safety and tolerability, another key objective is to establish proof of concept for the company's proprietary technology platform with (1) physiological data indicating that aerosolized KL4 surfactant is being effectively delivered into the lung of premature infants, and (2) acceptable performance by the novel capillary aerosol generator (CAG) technology in the neonatal intensive care unit (NICU). The company anticipates releasing the results of this trial and holding an investor conference call in approximately three to four weeks. AEROSURF is the company's investigational combination drug/device product that combines its synthetic KL4 surfactant with its proprietary CAG. If AEROSURF is successfully developed and approved, neonatologists will be able to administer aerosolized KL4 surfactant to premature infants receiving nCPAP, without having to use invasive methods (intubation and mechanical ventilation procedures that may each result in serious respiratory conditions and other complications) that currently are required to administer all surfactants. AEROSURF potentially will address this unmet medical need and may make possible the treatment of a significantly greater number of premature infants with RDS who could benefit from surfactant therapy but are currently not treated.

Discovery Laboratories Inc. Terminates Employment Agreement of Thomas F. Miller, Senior Vice President and Chief Operating Officer

Discovery Laboratories Inc. terminated the Employment Agreement of Thomas F. Miller, Senior Vice President and Chief Operating Officer, effective April 17, 2015.

Discovery Laboratories, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Discovery Laboratories Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported a net loss of $10.6 million or $0.15 per diluted share compared to a net loss of $11.7 million or $0.16 per basic and diluted share for the same period a year ago. Operating loss was $11,226,000 compared to $10,265,000 last year. Net cash outflows for the quarter ended December 31, 2014 were $10.2 million. Total revenue was $1,184,000 compared to $74,000 last year. For the year, the company reported a net loss of $44,058,000 or $0.56 per diluted share compared to a net loss of $45,215,000 or $0.82 per basic and diluted share for the same period a year ago. Operating loss was $43,258,000 compared to $44,508,000 last year. Total revenue was $2,835,000 compared to $388,000 last year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DSCO:US $1.24 USD -0.02

DSCO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $48.32 USD -0.14
View Industry Companies
 

Industry Analysis

DSCO

Industry Average

Valuation DSCO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 37.3x
Price/Book 5.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DISCOVERY LABORATORIES INC, please visit www.discoverylabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.